Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features

KRAS-mutated carcinomas comprise 35–40% of all colorectal carcinomas but little is known about their characteristics. The aim of this study was to examine the pathological and molecular features of KRAS-mutated colorectal carcinomas and to compare them with other carcinoma subgroups. KRAS mutation t...

Full description

Saved in:

Bibliographic Details
Published in:	Modern pathology 2013-06, Vol.26 (6), p.825-834
Main Authors:	Rosty, Christophe, Young, Joanne P, Walsh, Michael D, Clendenning, Mark, Walters, Rhiannon J, Pearson, Sally, Pavluk, Erika, Nagler, Belinda, Pakenas, David, Jass, Jeremy R, Jenkins, Mark A, Win, Aung Ko, Southey, Melissa C, Parry, Susan, Hopper, John L, Giles, Graham G, Williamson, Elizabeth, English, Dallas R, Buchanan, Daniel D
Format:	Article
Language:	eng
Subjects:	Adult Aged Biomarkers, Tumor - analysis Biomarkers, Tumor - genetics BRAF mutation Carcinoma - genetics Carcinoma - mortality Carcinoma - pathology Cell Differentiation Chi-Square Distribution Colonic Polyps - genetics Colonic Polyps - mortality Colonic Polyps - pathology colorectal cancer Colorectal Neoplasms - chemistry Colorectal Neoplasms - genetics Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology colorectal polyp DNA Methylation DNA Modification Methylases - analysis DNA Modification Methylases - genetics DNA Mutational Analysis DNA Repair Enzymes - analysis DNA Repair Enzymes - genetics Female Genetic Predisposition to Disease Humans Immunohistochemistry Kaplan-Meier Estimate KRAS mutation Male MGMT Microsatellite Instability Middle Aged molecular pathology Mutation Phenotype Prognosis Proportional Hazards Models Prospective Studies Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins p21(ras) ras Proteins - genetics Risk Factors survival analysis Time Factors Tumor Suppressor Proteins - analysis Tumor Suppressor Proteins - genetics Victoria
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	KRAS-mutated carcinomas comprise 35–40% of all colorectal carcinomas but little is known about their characteristics. The aim of this study was to examine the pathological and molecular features of KRAS-mutated colorectal carcinomas and to compare them with other carcinoma subgroups. KRAS mutation testing was performed in 776 incident tumors from the Melbourne Collaborative Cohort Study. O6-methylguanine DNA methyltransferase (MGMT) status was assessed using both immunohistochemistry and MethyLight techniques. Microsatellite instability (MSI) phenotype and BRAF V600E mutation status were derived from earlier studies. Mutation in KRAS codon 12 or codon 13 was present in 28% of colorectal carcinomas. Compared with KRAS wild-type carcinomas, KRAS-mutated carcinomas were more frequently observed in contiguity with a residual polyp (38 vs 21%; P
ISSN:	0893-3952 1530-0285